UNSPSC 51422360: Prednisolone acetate

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8B2807733D. European Medicines Agency schedules Prednisolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04014MIG. Prednisolone acetate generally arises in the molecular formula C23H30O6. The term 'prednisolone acetate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule prednisolone acetate under HS 29372100 and SITC 54153.

As of Q4 2014, PREDNISOLONE ACETATE remains US FDA's Preferred Term for this commodity. Prednisolone acetate bears US NLM identifiers UMLS ID C0071839 and NCI Concept Code C1202. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O.

UNSPSC 51422360 Prednisolone acetate is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged under it do not align with prednisolone acetate procurement — they center instead on naloxone and drug deactivation systems (Seminole County, Florida) and direct-to-manufacturer prescription program vendor capabilities (Texas Health and Human Services Commission). The code shows limited concrete activity in state and local procurement for the nominal product; the tagged opportunities represent a mismatch between the code classification and the actual work being solicited.

Seminole County posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. Texas HHS issued a Request for Information (RFI HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. These opportunities reflect opioid-crisis response and pharmacy benefit restructuring rather than prednisolone acetate supply. State and local procurement activity under this code does not currently support a focused business development strategy around prednisolone acetate itself.